Rufinamide-15N-d2, CAS 1795037-48-7

Formulation: A solid

Formal Name: 1-[(2,6-difluorophenyl)methyl-d2]-1H-1,2,3-triazole-4-carboxamide-15N

Purity: ≥99% deuterated forms (d1-d2)

Formula Markup: C10H6D2F2N3[15N]O

Formula Weight: 241,2

Shelf life (days): 1460

CAS Number: 1795037-48-7

Notes: Rufinamide-15N-d2 is intended for use as an internal standard for the quantification of rufinamide (Item No. 18870) by GC- or LC-MS. Rufinamide is an anticonvulsant.{58372} It inhibits the activation of voltage-gated sodium channel 1.1 (Nav1.1) when used at a concentration of 100 µM.{58370} Rufinamide inhibits Nav1.1, but not Nav1.2, Nav1.3, and Nav1.6, opening and increases the action potential threshold in primary rat hippocampal neurons. It is an inhibitor of carbonic anhydrase VA (CAVA; Ki = 343.8 nM) that is selective for CAVA over CAI and CAII (Kis = >10,000 nM for both).{58371} Rufinamide (100 µM) prolongs the preictal phase and reduces seizure-like event frequency in an in vitro model of epileptiform activity in rat hippocampal slices.{58369} It inhibits seizures induced by pentylenetetrazole (Item No. 18682) in a mouse model of epilepsy (ED50 = 54 mg/kg, i.p.) and reduces kainic acid-induced neuronal cell death in the mouse hippocampal CA3 region when used at doses of 25, 50, and 100 mg/kg.{58368,58367} Formulations containing rufinamide have been used in the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS).

• Artikelnummer: CAY33539
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 33539-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung